European CHMP Recommends Approval of CSL's Cell-Based Flu Vaccine, Aujemflu, Paving the Way for Commercialization
Breakthrough in European Market Access
The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Aujemflu, an influenza vaccine developed by CSL Seqirus. This recommendation is for the prevention of influenza in adults aged 50 and older and represents a key milestone towards final approval by the European Commission (EC). With a typical review period of 67 days, Aujemflu is expected to accelerate its commercial launch in the European market in the second half of 2026. This marks a turning point for CSL, solidifying its global presence in the influenza vaccine market, which annually affects the elderly population.
Innovative Combination of Cell Culture and Adjuvant
Aujemflu is an inactivated trivalent influenza vaccine that combines cell-culture technology with MF59, a squalene-based adjuvant. Unlike traditional egg-based methods, this allows for rapid, large-scale production, enabling a swift response to emerging viral strains. The inclusion of MF59 enhances the vaccine's efficacy by eliciting a robust antibody response in older adults with weakened immune systems. Its unique manufacturing process prevents egg adaptation, providing superior quality compared to existing standard treatments.
Demonstrated Immunogenicity and Non-Inferiority in Phase 3 Trials
This decision is based on data from a large, global Phase 3 trial (NCT06015282) involving 7,699 adults aged 50 and older. Clinical data demonstrated that Aujemflu exhibits superior immunogenicity compared to existing quadrivalent egg-based adjuvanted vaccines. Furthermore, it met all non-inferiority criteria when compared to Flublok, Sanofi's quadrivalent recombinant vaccine. This clinical evidence successfully convinced regulatory authorities that Aujemflu is an excellent alternative for addressing the immune gap in the elderly population.
Reshaping Flu Vaccine Supply Chains and Diversifying Revenue
CSL Group achieved approximately $2.2 billion in influenza vaccine revenue in fiscal year 2025 but has faced the urgent need to secure growth momentum due to recent declines in vaccination rates in the United States. The European approval of Aujemflu will serve as a catalyst for diversifying supply chains in a market currently dominated by Sanofi and GSK. Following final approval, the implementation of national procurement contracts and partnerships will further accelerate the trend towards a new generation of highly effective vaccines. Based on this, CSL is expected to significantly expand its market share in Europe and strengthen its role as a long-term cash cow.
The CHMP's positive opinion is a short-term regulatory catalyst that enhances the potential for commercialization of CSL Seqirus' next-generation pipeline in the global influenza vaccine market, valued at approximately $9 billion. Based on the results of a Phase 3 trial involving 7,699 participants, it has demonstrated superior immunogenicity compared to Sanofi's recombinant vaccine, Flublok, thereby establishing a unique competitive advantage in the elderly vaccine market. In the medium to long term, it provides an opportunity for CSL Seqirus to overcome the stagnation in its annual vaccine revenue of $2.2 billion due to declining vaccination rates in the United States and secure diversified growth drivers through new procurement contracts in Europe. The final approval by the European Commission (EC) and the subsequent commercial launch in the second half of the year will be a critical benchmark for future valuation adjustments of CSL Limited and potential decisions regarding the spin-off of its vaccine division.
Source: EMA (ema)